Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials

References

• O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-23
   PubMed Web of Science ®Google Scholar
• Oshaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12:1247-54
   PubMed Web of Science ®Google Scholar
• Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002;86:1367-72
   PubMed Web of Science ®Google Scholar
• Perez EA. Current management of metastatic breast cancer. Semin Oncol 1999;26(4 Suppl 12):1-10
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998;339:974-84
   PubMed Web of Science ®Google Scholar
• Marty M, Espie M, Cottu PH, et al. Optimizing chemotherapy for patients with advanced breast cancer. Oncology 1999;57(Suppl 1):21-6
   PubMedGoogle Scholar
• Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-15
   PubMed Web of Science ®Google Scholar
• Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 1992;35:1505-9
   PubMed Web of Science ®Google Scholar
• Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-93
   PubMed Web of Science ®Google Scholar
• Chan S, Romieu G, Huober J, et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 2009;27:1753-60
   PubMed Web of Science ®Google Scholar
• Wardley AM, Pivot X, Morales-Vasquez F, et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:976-83
   PubMed Web of Science ®Google Scholar
• Mavroudis D, Papakotoulas P, Ardavanis A, et al. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. Ann Oncol 2010;21:48-54
   PubMed Web of Science ®Google Scholar
• Stemmler HJ, diGioia D, Freier W, et al. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. Br J Cancer 2011;104:1071-8
   PubMed Web of Science ®Google Scholar
• Bachelot T, Bajard A, Ray-Coquard I, et al. Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer. Oncology 2011;80:262-8
   PubMed Web of Science ®Google Scholar
• Pajk B, Cufer T, Canney P, et al. Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial. Breast 2008;17:180-5
   PubMed Web of Science ®Google Scholar
• Stockler MR, Harvey VJ, Francis PA, et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 2011 Dec 1;29:4498-504
   Google Scholar
• Zhou WB, Ding Q, Chen L, et al. Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials. Breast Cancer Res Treat 2011;128:625-31
   PubMed Web of Science ®Google Scholar
• Zhou WB, Xue DQ, Liu XA, et al. The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: a meta-analysis. J Cancer Res Clin Oncol 2011;137:1053-60
   PubMed Web of Science ®Google Scholar
• Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007;26:53-77
   PubMed Web of Science ®Google Scholar
• Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010;10:337
   PubMed Web of Science ®Google Scholar
• Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997;127:820-6
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88
   PubMed Web of Science ®Google Scholar
• Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48
   PubMed Web of Science ®Google Scholar
• Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998;4:1013-19
   PubMed Web of Science ®Google Scholar
• Kurosumi M, Tabei T, Suemasu K, et al. Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep 2000;7:945-8
   PubMed Web of Science ®Google Scholar